BLIS Technologies Ltd - Company Profile
Powered by 
All the sales intelligence you need on BLIS Technologies Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how BLIS Technologies Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with BLIS Technologies Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
BLIS Technologies Ltd (BLIS) develops, manufactures, and sells advanced probiotics and ingredients for the oral health care market. The company's main activities include the production and distribution of probiotics aimed at supporting oral, dental, and skin health. BLIS offers a range of products under the brand names BLIS K12, BLIS Q24, and BLIS M18. These products are designed for use in healthcare applications, specifically targeting concerns such as throat health, dental hygiene, and skin microbiome balance. It sells its products to manufacturers and wholesale customers, providing them with sales training and support. The company’s manufacturing team produce Blis finished products, which are distributed to multiple entities. Its operations are spread across Europe, the Middle East, Africa, North America and Asia Pacific. BLIS is headquartered in Dunedin, Otago, New Zealand.
Headquarters
New Zealand
Address
Ground Floor, 399 Moray Place, Dunedin Central, Otago, 9016
Website
blis.co.nz
Telephone
64 3 4740988
Industry
Ingredients
Ticker Symbol & Exchange
BLT (NZE)
Revenue (2025)
$7.6M
9.7%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
29.7%
(2025 vs 2024)
Market Cap*
$11.7M
Net Profit Margin (2025)
XYZ
18.4%
(2025 vs 2024)
* As of and is in US$
Products and Services
| Products | Brands |
|---|---|
| Streptococcus Salivarius K12 | BLIS K12 |
| Streptococcus Salivarius M18 | BLIS M18 |
| Micrococcus Luteus Q24 | BLIS Q24 |
Competitor Comparison
| Key Parameters | BLIS Technologies Ltd | DSM-Firmenich AG | Probiotec Ltd | Bioxyne Ltd | Douglas Pharmaceuticals Ltd |
|---|---|---|---|---|---|
| Headquarters | New Zealand | Switzerland | Australia | Australia | New Zealand |
| City | Dunedin | Kaiseraugst | Melbourne | Sydney | Auckland |
| State/Province | Otago | Aargau | Victoria | New South Wales | Auckland |
| No. of Employees | - | 28,214 | 111 | 16 | 700 |
| Entity Type | Public | Public | Private | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Geoff Plunket | Chairman | Executive Board | 2021 | - |
| Scott Johnson | Chief Executive Officer | Senior Management | 2024 | - |
| Richard Wingham | Chief Financial Officer | Senior Management | 2017 | - |
| John Hale | Chief Technology Officer | Senior Management | 2011 | - |
| Jennifer Walker | Chief Revenue Officer | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer